Switzerland’s limited medical use program allows MDMA, LSD, and psilocybin treatments for patients with serious, mostly incurable conditions when no effective alternatives remain. Launched in 2014 with 2 doctors, it expanded to ~100 providers by 2024, delivering 1,660 treatments to 723 patients that year. Patients typically receive 2–4 sessions within 12 months. The program’s tightly regulated framework, covering legal requirements, physician training, costs, and patient outcomes, offers lessons for other countries exploring restricted psychedelic access.